Bicyclic MIF Modulators via Segmented Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel compounds and pharmaceutical compositions that can effectively modulate Macrophage Migration Inhibitory Factor (MIF) expression levels to treat various disorders associated with high or low MIF levels, as existing MIF inhibitors have limitations in diversity and therapeutic efficacy.
Innovation Solution
Development of bicyclic and fused ring compounds that interact with MIF's receptor CD74, using computer-aided design and synthetic organic chemistry to create potent inhibitors and agonists, including benzoxazolone derivatives, to modulate MIF expression and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing MIF inhibitors are used, then MIF activity is inhibited, but the diversity and therapeutic efficacy are limited
Solution Approach 1:
The patent segments the MIF inhibitor development into multiple chemical series (benzoxazolone derivatives, indole compounds, pyridine compounds, etc.), each targeting different aspects of MIF activity. This segmentation allows for diverse structural approaches while maintaining therapeutic efficacy through multiple mechanisms of action.
Solution Approach 2:
The patent employs composite chemical structures combining heterocyclic rings (oxazolone, indole, pyridine) with various functional groups and substituents. These composite molecular structures provide both diversity in chemical space and targeted efficacy through specific structure-activity relationships.
2Reliability
If novel bicyclic and fused ring compounds are developed, then MIF modulation capability is enhanced, but the complexity of compound synthesis increases
Solution Approach 1:
The patent employs computer-aided design and virtual screening to pre-identify promising compound structures before synthesis. This preliminary computational action filters out ineffective structures, reducing the number of compounds requiring complex synthesis while maintaining high MIF modulation capability.
Solution Approach 2:
The patent uses computer-aided design software and computational models as intermediaries between the desired MIF modulation effect and the actual chemical synthesis. This intermediary allows for optimization of molecular structures in silico, reducing the need for trial-and-error synthesis and lowering overall synthesis complexity.
Data Source
AI summary
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.